Home » BioMarin’s Hemophilia A Treatment Nabs Orphan Drug Status
BioMarin’s Hemophilia A Treatment Nabs Orphan Drug Status
The European Commission has granted orphan drug designation to BioMarin’s BMN 270, a gene therapy treatment for hemophilia A.
Earlier this month, the FDA awarded BMN 270 the same designation.
An AAV 5 factor VIII vector, BMN 270 is in a Phase 1/2 study evaluating the candidate in patients with severe hemophilia. The therapy is intended to restore factor VIII plasma concentrations.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May